Pluvicto savings card: as little as $0 a treatment with commercial insurance

Pluvicto is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Pluvicto is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand namePluvicto

Authorized genericlutetium lu 177 vipivotide tetraxetan

Regular genericlutetium lu 177 vipivotide tetraxetan

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Pluvicto?

The original

–

Brand nameThe maker’s card

Novartis Patient Support Co-Pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $15,000 per course of treatment off your co-pay.

Or call 1-844-638-7222.

In the maker’s words

“If you have private insurance, you could be eligible for co-pay support and may pay as little as $0 for your PLUVICTO treatment.”

From the maker’s offer on us.pluvicto.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Pluvicto itself, from the same company, sold without the brand name, and usually for less. For now Pluvicto is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

PSMA-positive prostate cancer that has spread

What the FDA label says

PLUVICTO is a radioligand therapeutic agent indicated:

Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer

in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.

Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer

for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and
- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

Source: the FDA label for Pluvicto (Novartis Pharmaceuticals Corporation), August 12, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/pluvicto/